Demodex Mites in Acne Patients and Herbal Extract Susceptibility

NCT07845149 | Not Yet Recruiting

• 1 other identifier: Demodex-Acne-Assiut-2026
• Study Type: observational
• Target: 80
• Locations: 0 countries
• Sites: N/A

Brief Summary

This case-control study aims to detect the presence and density of Demodex mites in patients with acne, identify the species using molecular methods, and evaluate the in vitro survival time of live mites exposed to medicinal herbal extracts.

Conditions

Acne; Demodex Infestation

Keywords

Acne; Assiut; In vitro susceptibility; Demodex; Herbal extracts

Outcome Measures

Primary Outcomes (3)

• Prevalence of Demodex infestation

  Proportion of participants with Demodex mites detected by standardized skin surface biopsy.

  Baseline

• Mean Demodex density

  Mean number of Demodex mites per cm² of skin surface.

  Baseline

• Mean in vitro survival time of Demodex mites

  Mean survival time in minutes of live Demodex mites exposed to the medicinal herbal extracts.

  Baseline

Secondary Outcomes (6)

• Distribution of Demodex species

  Baseline

• Mean mite density according to acne severity

  Baseline

• Mean survival time at 5% herbal extract concentration

  Baseline

• Mean survival time at 10% herbal extract concentration

  Baseline

• Mean survival time at 25% herbal extract concentration

  Baseline

Study Arms (2)

Patients with Acne

Patients with clinically diagnosed acne of any severity (mild, moderate, or severe) who will undergo standardized skin surface biopsy for Demodex detection and density calculation.

Healthy Controls

Age- and sex-matched healthy individuals without dermatosis.

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)
• Sampling Method: Non-Probability Sample

Study Population

Adult patients with clinically diagnosed acne vulgaris attending the dermatology outpatient clinic at Assiut University Hospital, and age- and sex-matched healthy controls.

You may qualify if:

• \- Age 18 to 45 years
• Clinically diagnosed acne vulgaris of any severity (cases)
• Age- and sex-matched healthy individuals without dermatosis or pruritus (controls)
• Written informed consent

You may not qualify if:

• \- Use of topical anti-acne or acaricidal treatments within the last 4 weeks
• Use of systemic antibiotics or systemic retinoids within the last 3 months

Sponsors & Collaborators

• Assiut University: lead

MeSH Terms

Conditions

Acne Vulgaris

Condition Hierarchy (Ancestors)

Acneiform Eruptions; Skin Diseases; Skin and Connective Tissue Diseases; Sebaceous Gland Diseases

Study Officials

• Magda M Atiaa, prof

  Medical parasitology Department, Assiut University Hospitals

  STUDY CHAIR

Central Study Contacts

Marina G shawqy, Resident

CONTACT

+20 12 76121351; Marina.gamil@aun.edu.eg

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Resident Physician, Department of medical Parasitology

Study Record Dates

• First Submitted: September 22, 2026
• First Posted: September 28, 2026
• Study Start: September 26, 2026
• Primary Completion (Estimated): September 26, 2027
• Study Completion (Estimated): February 10, 2028
• Last Updated: September 28, 2026

Record last verified: 2026-09

Data Sharing

• IPD Sharing: Will not share